342
Skiba M, Duchêne D, Puisieux F, Wouessidjewe D (1996) Development of a new colloidal
drug carrier from chemically modified cyclodextrins: nanospheres and influence of physicochemical and technological factors on particle size. Int J Pharm 129:113–121. https://doi.
org/10.1016/0378-5173(95)04272-5
Spada G, Gavini E, Cossu M, Rassu G, Giunchedi P (2012) Solid lipid nanoparticles with and
without hydroxypropyl β-cyclodextrin: a comparative study of nanoparticles designed for
colonic drug delivery. Nanotechnology:23. https://doi.org/10.1088/0957-4484/23/9/095101
Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28. https://doi.org/10.1016/
S0169-409X(98)00092-1
Tao HQ, Meng Q, Li MH, Yu H, Liu MF, Du D, Sun SL, Yang HC, Wang YM, Ye W, Yang LZ,
Zhu DL, Jiang CL, Peng HS (2013) HP-β-cyclodextrin-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemiareperfusion injury in rats. Naunyn Schmiedeberg’s Arch Pharmacol 386:61–70. https://doi.
org/10.1007/s00210-012-0804-5
Teijeiro-Osorio D, Remuñán-López C, Alonso MJ (2009) Chitosan/cyclodextrin nanoparticles can
efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 71:257–263. https://
doi.org/10.1016/J.EJPB.2008.09.020
Trapani A, Garcia-Fuentes M, Alonso MJ (2008) Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19. https://doi.
org/10.1088/0957-4484/19/18/185101
Trapani A, Sitterberg J, Bakowsky U, Kissel T (2009) The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int J Pharm 375:97–106. https://doi.org/10.1016/j.
ijpharm.2009.03.041
Trapani A, Lopedota A, Franco M, Cioffi N, Ieva E, Garcia-Fuentes M, Alonso MJ (2010) A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the
oral delivery of small peptides. Eur J Pharm Biopharm 75:26–32. https://doi.org/10.1016/j.
ejpb.2010.01.010
Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, Kanabar D, Garcia JV,
Mitragotri S, Muth A, Gupta V (2019) Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol
122:338–347. https://doi.org/10.1016/j.ijbiomac.2018.10.181
Vakhariya RR, Talokar SS, Salunkhe VR, Magdum CS (2017) Formulation development and optimization of simvastatin loaded solid lipid nanoparticles. Asian J Res Pharm Sci 7:49. https://
doi.org/10.5958/2231-5659.2017.00008.x
Varan G, Öncül S, Ercan A, Benito JM, Ortiz Mellet C, Bilensoy E (2016) Cholesterol-targeted
anticancer and apoptotic effects of anionic and polycationic amphiphilic cyclodextrin nanoparticles. J Pharm Sci 105:3172–3182. https://doi.org/10.1016/j.xphs.2016.06.021
Varan G, Patrulea V, Borchard G, Bilensoy E (2018) Cellular interaction and tumoral penetration
properties of cyclodextrin nanoparticles on 3D breast tumor model. Nanomaterials 8:1–18.
https://doi.org/10.3390/nano8020067
Wang Y, Wong JF, Teng X, Lin XZ, Yang H (2003) “Pulling” nanoparticles into water: phase transfer of oleic acid stabilized monodisperse nanoparticles into aqueous solutions of α-cyclodextrin.
Nano Lett 3:1555–1559. https://doi.org/10.1021/nl034731j
Wang T, Zhang C, Liang XJ, Liang W, Wu Y (2011) Hydroxypropyl-β-cyclodextrin copolymers
and their nanoparticles as doxorubicin delivery system. J Pharm Sci 100:1067–1079. https://
doi.org/10.1002/jps.22352
Wang X, Chen C, Huo D, Qian H, Ding Y, Hu Y, Jiang X (2012) Synthesis of β-cyclodextrin
modified chitosan-poly(acrylic acid) nanoparticles and use as drug carriers. Carbohydr Polym
90:361–369. https://doi.org/10.1016/j.carbpol.2012.05.052
Wang Y, Li H, Jin Q, Ji J (2016a) Intracellular host-guest assembly of gold nanoparticles triggered
by glutathione. Chem Commun 52:582–585. https://doi.org/10.1039/c5cc07195j
A. Pandey
Skiba M, Duchêne D, Puisieux F, Wouessidjewe D (1996) Development of a new colloidal
drug carrier from chemically modified cyclodextrins: nanospheres and influence of physicochemical and technological factors on particle size. Int J Pharm 129:113–121. https://doi.
org/10.1016/0378-5173(95)04272-5
Spada G, Gavini E, Cossu M, Rassu G, Giunchedi P (2012) Solid lipid nanoparticles with and
without hydroxypropyl β-cyclodextrin: a comparative study of nanoparticles designed for
colonic drug delivery. Nanotechnology:23. https://doi.org/10.1088/0957-4484/23/9/095101
Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28. https://doi.org/10.1016/
S0169-409X(98)00092-1
Tao HQ, Meng Q, Li MH, Yu H, Liu MF, Du D, Sun SL, Yang HC, Wang YM, Ye W, Yang LZ,
Zhu DL, Jiang CL, Peng HS (2013) HP-β-cyclodextrin-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemiareperfusion injury in rats. Naunyn Schmiedeberg’s Arch Pharmacol 386:61–70. https://doi.
org/10.1007/s00210-012-0804-5
Teijeiro-Osorio D, Remuñán-López C, Alonso MJ (2009) Chitosan/cyclodextrin nanoparticles can
efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 71:257–263. https://
doi.org/10.1016/J.EJPB.2008.09.020
Trapani A, Garcia-Fuentes M, Alonso MJ (2008) Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19. https://doi.
org/10.1088/0957-4484/19/18/185101
Trapani A, Sitterberg J, Bakowsky U, Kissel T (2009) The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int J Pharm 375:97–106. https://doi.org/10.1016/j.
ijpharm.2009.03.041
Trapani A, Lopedota A, Franco M, Cioffi N, Ieva E, Garcia-Fuentes M, Alonso MJ (2010) A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the
oral delivery of small peptides. Eur J Pharm Biopharm 75:26–32. https://doi.org/10.1016/j.
ejpb.2010.01.010
Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, Kanabar D, Garcia JV,
Mitragotri S, Muth A, Gupta V (2019) Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol
122:338–347. https://doi.org/10.1016/j.ijbiomac.2018.10.181
Vakhariya RR, Talokar SS, Salunkhe VR, Magdum CS (2017) Formulation development and optimization of simvastatin loaded solid lipid nanoparticles. Asian J Res Pharm Sci 7:49. https://
doi.org/10.5958/2231-5659.2017.00008.x
Varan G, Öncül S, Ercan A, Benito JM, Ortiz Mellet C, Bilensoy E (2016) Cholesterol-targeted
anticancer and apoptotic effects of anionic and polycationic amphiphilic cyclodextrin nanoparticles. J Pharm Sci 105:3172–3182. https://doi.org/10.1016/j.xphs.2016.06.021
Varan G, Patrulea V, Borchard G, Bilensoy E (2018) Cellular interaction and tumoral penetration
properties of cyclodextrin nanoparticles on 3D breast tumor model. Nanomaterials 8:1–18.
https://doi.org/10.3390/nano8020067
Wang Y, Wong JF, Teng X, Lin XZ, Yang H (2003) “Pulling” nanoparticles into water: phase transfer of oleic acid stabilized monodisperse nanoparticles into aqueous solutions of α-cyclodextrin.
Nano Lett 3:1555–1559. https://doi.org/10.1021/nl034731j
Wang T, Zhang C, Liang XJ, Liang W, Wu Y (2011) Hydroxypropyl-β-cyclodextrin copolymers
and their nanoparticles as doxorubicin delivery system. J Pharm Sci 100:1067–1079. https://
doi.org/10.1002/jps.22352
Wang X, Chen C, Huo D, Qian H, Ding Y, Hu Y, Jiang X (2012) Synthesis of β-cyclodextrin
modified chitosan-poly(acrylic acid) nanoparticles and use as drug carriers. Carbohydr Polym
90:361–369. https://doi.org/10.1016/j.carbpol.2012.05.052
Wang Y, Li H, Jin Q, Ji J (2016a) Intracellular host-guest assembly of gold nanoparticles triggered
by glutathione. Chem Commun 52:582–585. https://doi.org/10.1039/c5cc07195j
A. Pandey